通过培养确诊肺炎链球菌疾病监测评估儿童13价肺炎球菌结合疫苗接种效果
本研究在台湾某医疗中心2012至2016年前瞻性收集儿童肺炎链球菌临床分离株,评估PCV13免疫对培养确诊肺炎链球菌疾病(CCPD)的影响。共纳入473例CCPD患者(含58例侵袭性肺炎链球菌疾病IPD),CCPD发病率从2012年每万例住院71.7例降至2016年27.0例。PCV13额外血清型比例从2012年52.0%显著降至2015年21.7%,2016年因19A血清型略升至26.7%(P<0.0001)。非疫苗血清型(NVT)比例从2012年18.4%显著增至2016年66.7%,但NVT所致CCPD发病率增加不显著(P=0.0885)。
要点
- CCPD监测可更全面评估肺炎球菌免疫规划效果。
- PCV13使用后血清型替换迅速发生。
- NVT感染发病率在儿童中未见显著增加。
核心结论
- PCV13逐步纳入国家免疫规划可有效减少儿童总体肺炎链球菌疾病。
- CCPD监测在评估肺炎球菌免疫总体影响方面优于单独IPD监测。
- PCV13使用后血清型替换迅速出现,但NVT感染发病率未显著增加。
研究设计与样本
- 前瞻性临床微生物学研究,2012至2016年在台湾某医疗中心开展。
- 前瞻性收集儿童肺炎链球菌临床分离株,进行血清分型、多位点序列分型和抗菌药物敏感性试验。
- 共识别473例CCPD患者,其中58例为IPD。
主要发现
- CCPD发病率从2012年每万例住院71.7例降至2016年27.0例。
- PCV13额外血清型比例从2012年52.0%显著降至2015年21.7%,2016年因19A血清型略升至26.7%(P<0.0001)。
- NVT比例从2012年18.4%显著增至2016年66.7%,但NVT所致CCPD发病率增加不显著(P=0.0885)。
- 基因分型鉴定出主要NVT的优势克隆为ST6315A、ST8315B和ST166/33823A。
- PCV13血清型的青霉素非敏感率显著高于NVT(P<0.0001)。
临床怎么用
- 在儿童肺炎球菌疾病监测中,可优先采用CCPD监测以全面评估免疫规划效果。
- PCV13免疫规划实施后需持续监测血清型替换及NVT发病率变化。
- 关注PCV13血清型较高的青霉素非敏感率,指导抗菌药物合理使用。
局限性
- 本研究为单中心研究,结果外推需谨慎。
- 研究期间为2012至2016年,后续血清型动态可能变化。
- NVT发病率增加未达统计学显著,需更长监测验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study aimed to investigate the impact of 13-valent pneumococcal conjugate vaccine (PCV13) immunization on the overall pneumococcal disease in children in Taiwan by surveillance of culture-confirmed pneumococcal disease (CCPD). This study was conducted in a medical center from 2012 to 2016. Clinical isolates of Streptococcus pneumoniae were prospectively collected from pediatric patients. Serotyping, multi-locus sequence typing, and antimicrobial susceptibility testing were performed. A total of 473 patients with CCPD, including 58 with invasive pneumococcal disease (IPD), were identified. The incidence of CCPD per 10,000 admissions decreased from 71.7 in 2012 to 27.0 in 2016. The proportion of additional PCV13 serotypes significantly decreased from 52.0% in 2012 to 21.7% in 2015 but increased slightly to 26.7% because of serotype 19A in 2016 (P < 0.0001). The proportion of non-vaccine serotypes (NVTs) increased significantly from 18.4% in 2012 to 66.7% in 2016, but the increase of the incidence of CCPD caused by NVTs was not considered significant (P = 0.0885). Genotyping identified predominant clones, ST6315A, ST8315B, and ST166/33823A, for major NVTs. The penicillin non-susceptibility of PCV13 serotypes was significantly higher than that of NVTs (P < 0.0001). Surveillance of CCPD appears superior to IPD alone for evaluation of the overall impact of pneumococcal immunization. Serotype replacement occurred quickly after the use of PCV13, while the incidence of NVT infection did not show a significant increase in children over the years. The gradual introduction of PCV13 into national immunization program is effective in reducing overall pneumococcal disease in children.
引用
- Chen CH, Su LH, Li HC, et al. Evaluation of the impact of 13-valent pneumococcal conjugate vaccine immunization in children by surveillance of culture-confirmed pneumococcal disease: A prospective clinical microbiological study. Vaccine. 2019. PMID: 31377076. doi:10.1016/j.vaccine.2019.07.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。